<DOC>
	<DOCNO>NCT02448303</DOCNO>
	<brief_summary>Pembrolizumab alone combination acalabrutinib subject advance non-small cell lung cancer .</brief_summary>
	<brief_title>Pembrolizumab Alone In Combination With Acalabrutinib ( ACP-196 ) Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Men woman ≥ 18 year age ECOG performance status 0 1 Histologically confirm recurrent metastatic NSCLC ( adenocarcinoma , large cell , squamous cell , otherwise specify ) either progress platinumbased chemotherapy Received least 1 platinumbased chemotherapy regimen . Note : Subjects EGFR mutation ALK translocation require received prior therapy appropriate TKI ; prior platinumbased chemotherapy require specific patient population Prior malignancy ( lung cancer ) , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year Known central nervous system metastases and/or carcinomatous meningitis Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease , partial complete bowel obstruction , gastric restriction bariatric surgery , gastric bypass Breastfeeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>